Host and viral modulation of RIG-I-mediated antiviral immunity

Frontiers in Immunology

Volumn 7, Issue JAN, 2017, Pages

  Liu, Yiliu ^a,b   Olagnier, David ^a,b,c   Lin, Rongtuan ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Antiviral; Infection; Innate immunity; RIG I; Type I IFNs; Virus host interaction

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 10; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN;

DENGUE VIRUS; EBOLAVIRUS; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INNATE IMMUNITY; MASS SPECTROMETRY; MEASLES VIRUS; MOLLUSCUM CONTAGIOSUM VIRUS; NONHUMAN; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VESICULOVIRUS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 85012069968     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00662     Document Type: Review

References (152)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863.
2. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 5:730-7. doi:10.1038/ni1087.
3. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity (2011) 34:680-92. doi:10.1016/j.immuni.2011.05.003.
4. Takeda K, Akira S. TLR signaling pathways. Semin Immunol (2004) 16:3-9. doi:10.1016/j.smim.2003.10.003.
5. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity (2011) 34:665-79. doi:10.1016/j.immuni.2011.05.007.
6. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2013) 339:786-91. doi:10.1126/science.1232458.
7. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol (2010) 11:997-1004. doi:10.1038/ni.1932.
8. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604.
9. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol (2008) 8:911-22. doi:10.1038/nri2436.
10. Chan YK, Gack MU. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol (2016) 14:360-73. doi:10.1038/nrmicro.2016.45.
11. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140:805-20. doi:10.1016/j.cell.2010.01.022.
12. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, Pyle AM. Structural insights into RNA recognition by RIG-I. Cell (2011) 147:409-22. doi:10.1016/j.cell.2011.09.023.
13. Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M Jr, Patel SS, et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature (2011) 479:423-7. doi:10.1038/nature10537.
14. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B, et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell (2011) 147:423-35. doi:10.1016/j.cell.2011.09.039.
15. Belgnaoui SM, Paz S, Hiscott J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol (2011) 23:564-72. doi:10.1016/j.coi.2011.08.001.
16. Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol (2010) 20:4-22. doi:10.1002/rmv.633.
17. Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev (2009) 227:54-65. doi:10.1111/j.1600-065X.2008.00727.x.
18. Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 80:5168-78. doi:10.1128/JVI.02199-05.
19. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, Liu DX. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis (2011) 5:e926. doi:10.1371/journal.pntd.0000926.
20. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314:994-7. doi:10.1126/science.1132505.
21. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 31:25-34. doi:10.1016/j.immuni.2009.05.008.
22. Weber M, Gawanbacht A, Habjan M, Rang A, Borner C, Schmidt AM, et al. Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe (2013) 13:336-46. doi:10.1016/j.chom.2013.01.012.
23. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 314:997-1001. doi:10.1126/science.1132998.
24. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature (2014) 514:372-5. doi:10.1038/nature13590.
25. Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog (2013) 9:e1003298. doi:10.1371/journal.ppat.1003298.
26. Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, et al. Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol (2014) 88:4180-94. doi:10.1128/JVI.03114-13.
27. Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE, Wong T, et al. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J Virol (2015) 89:10612-24. doi:10.1128/JVI.01526-15.
28. Pinto AK, Brien JD, Lam CY, Johnson S, Chiang C, Hiscott J, et al. Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection. MBio (2015) 6:e1316-1315. doi:10.1128/mBio.01316-15.
29. Chiang C, Beljanski V, Yin K, Olagnier D, Ben Yebdri F, Steel C, et al. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol (2015) 89:8011-25. doi:10.1128/JVI.00845-15.
30. Hochheiser K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, et al. Cutting edge: the RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination. J Immunol (2016) 196:2439-43. doi:10.4049/jimmunol.1501958.
31. Melchjorsen J, Rintahaka J, Soby S, Horan KA, Poltajainen A, Ostergaard L, et al. Early innate recognition of herpes simplex virus in human primary macrophages is mediated via the MDA5/MAVS-dependent and MDA5/MAVS/RNA polymerase III-independent pathways. J Virol (2010) 84:11350-8. doi:10.1128/JVI.01106-10.
32. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell (2009) 138:576-91. doi:10.1016/j.cell.2009.06.015.
33. Liu Y, Goulet ML, Sze A, Bel Hadj S, Belgnaoui SM, Lababidi RR, et al. RIG-I mediated STING up-regulation restricts HSV-1 infection. J Virol (2016) 90:9406-19. doi:10.1128/JVI.00748-16.
34. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2010) 11:63-9. doi:10.1038/ni.1824.
35. Pothlichet J, Meunier I, Davis BK, Ting JP, Skamene E, von Messling V, et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog (2013) 9:e1003256. doi:10.1371/journal.ppat.1003256.
36. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature (2005) 437:1167-72. doi:10.1038/nature04193.
37. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell (2005) 122:669-82. doi:10.1016/j.cell.2005.08.012.
38. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 27:693-733. doi:10.1146/annurev.immunol.021908.132641.
39. Paz S, Vilasco M, Werden SJ, Arguello M, Joseph-Pillai D, Zhao T, et al. A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cell Res (2011) 21:895-910. doi:10.1038/cr.2011.2.
40. Zhao T, Yang L, Sun Q, Arguello M, Ballard DW, Hiscott J, et al. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol (2007) 8:592-600. doi:10.1038/ni1465.
41. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J (1998) 17:1087-95. doi:10.1093/emboj/17.4.1087.
42. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A (2007) 104:582-7. doi:10.1073/pnas.0606699104.
43. Cui S, Eisenacher K, Kirchhofer A, Brzozka K, Lammens A, Lammens K, et al. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. Mol Cell (2008) 29:169-79. doi:10.1016/j.molcel.2007.10.032.
44. Patel JR, Jain A, Chou YY, Baum A, Ha T, Garcia-Sastre A. ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. EMBO Rep (2013) 14:780-7. doi:10.1038/embor.2013.102.
45. Peisley A, Wu B, Yao H, Walz T, Hur S. RIG-I forms signaling-competent filaments in an ATP-dependent, ubiquitin-independent manner. Mol Cell (2013) 51:573-83. doi:10.1016/j.molcel.2013.07.024.
46. Anchisi S, Guerra J, Garcin D. RIG-I ATPase activity and discrimination of self-RNA versus non-self-RNA. MBio (2015) 6:e02349. doi:10.1128/mBio.02349-14.
47. Lässig C, Matheisl S, Sparrer KMJ, de Oliveira Mann CC, Moldt M, Patel JR, et al. Correction: ATP hydrolysis by the viral RNA sensor RIG-I prevents unintentional recognition of self-RNA. Elife (2016) 5:e14954. doi:10.7554/eLife.14954.
48. Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, Cui S, et al. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A (2008) 105:16743-8. doi:10.1073/pnas.0804947105.
49. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale M Jr. The mitochondrial targeting chaperone 14-3-3epsilon regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe (2012) 11:528-37. doi:10.1016/j.chom.2012.04.006.
50. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature (2007) 446:916-20. doi:10.1038/nature05732.
51. Oshiumi H, Matsumoto M, Hatakeyama S, Seya T. Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J Biol Chem (2009) 284:807-17. doi:10.1074/jbc. M804259200.
52. Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, Seya T. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe (2010) 8:496-509. doi:10.1016/j.chom.2010.11.008.
53. Gao D, Yang YK, Wang RP, Zhou X, Diao FC, Li MD, et al. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I. PLoS One (2009) 4:e5760. doi:10.1371/journal.pone.0005760.
54. Oshiumi H, Miyashita M, Matsumoto M, Seya T. A distinct role of Riplet-mediated K63-linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog (2013) 9:e1003533. doi:10.1371/journal.ppat.1003533.
55. Kuniyoshi K, Takeuchi O, Pandey S, Satoh T, Iwasaki H, Akira S, et al. Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in RIG-I-mediated antiviral innate immunity. Proc Natl Acad Sci U S A (2014) 111:5646-51. doi:10.1073/pnas.1401674111.
56. Zhu J, Zhang Y, Ghosh A, Cuevas RA, Forero A, Dhar J, et al. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity (2014) 40:936-48. doi:10.1016/j.immuni.2014.05.007.
57. Ibsen MS, Gad HH, Andersen LL, Hornung V, Julkunen I, Sarkar SN, et al. Structural and functional analysis reveals that human OASL binds dsRNA to enhance RIG-I signaling. Nucleic Acids Res (2015) 43:5236-48. doi:10.1093/nar/gkv389.
58. Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell (2010) 141:315-30. doi:10.1016/j.cell.2010.03.029.
59. Peisley A, Wu B, Xu H, Chen ZJ, Hur S. Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature (2014) 509:110-4. doi:10.1038/nature13140.
60. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep (2008) 9:930-6. doi:10.1038/embor.2008.136.
61. Lin W, Zhang J, Lin H, Li Z, Sun X, Xin D, et al. Syndecan-4 negatively regulates antiviral signalling by mediating RIG-I deubiquitination via CYLD. Nat Commun (2016) 7:11848. doi:10.1038/ncomms11848.
62. Cui J, Song Y, Li Y, Zhu Q, Tan P, Qin Y, et al. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. Cell Res (2014) 24:400-16. doi:10.1038/cr.2013.170.
63. Fan Y, Mao R, Yu Y, Liu S, Shi Z, Cheng J, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med (2014) 211:313-28. doi:10.1084/jem.20122844.
64. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci U S A (2007) 104:7500-5. doi:10.1073/pnas.0611551104.
65. Wang W, Jiang M, Liu S, Zhang S, Liu W, Ma Y, et al. RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDs to mediate RIG-I degradation. Proc Natl Acad Sci U S A (2016) 113:9581-6. doi:10.1073/pnas.1604277113.
66. Inn KS, Gack MU, Tokunaga F, Shi M, Wong LY, Iwai K, et al. Linear ubiquitin assembly complex negatively regulates RIG-I-and TRIM25-mediated type I interferon induction. Mol Cell (2011) 41:354-65. doi:10.1016/j.molcel.2010.12.029.
67. Pauli EK, Chan YK, Davis ME, Gableske S, Wang MK, Feister KF, et al. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci Signal (2014) 7:ra3. doi:10.1126/scisignal.2004577.
68. Gack MU, Nistal-Villan E, Inn KS, Garcia-Sastre A, Jung JU. Phosphorylation-mediated negative regulation of RIG-I antiviral activity. J Virol (2010) 84:3220-9. doi:10.1128/JVI.02241-09.
69. Nistal-Villan E, Gack MU, Martinez-Delgado G, Maharaj NP, Inn KS, Yang H, et al. Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. J Biol Chem (2010) 285:20252-61. doi:10.1074/jbc. M109.089912.
70. Sun Z, Ren H, Liu Y, Teeling JL, Gu J. Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. J Virol (2011) 85:1036-47. doi:10.1128/JVI.01734-10.
71. Zhang X, Yu H, Zhao J, Li X, Li J, He J, et al. IKK negatively regulates RIG-I via direct phosphorylation. J Med Virol (2016) 88:712-8. doi:10.1002/jmv.24376.
72. Maharaj NP, Wies E, Stoll A, Gack MU. Conventional protein kinase C-alpha (PKC-alpha) and PKC-beta negatively regulate RIG-I antiviral signal transduction. J Virol (2012) 86:1358-71. doi:10.1128/JVI.06543-11.
73. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, Finberg RW, et al. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity (2013) 38:437-49. doi:10.1016/j.immuni.2012.11.018.
74. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (2009) 325:834-40. doi:10.1126/science.1175371.
75. Liu HM, Jiang F, Loo YM, Hsu S, Hsiang TY, Marcotrigiano J, et al. Regulation of retinoic acid inducible gene-I (RIG-I) activation by the histone deacetylase 6. EBioMedicine (2016) 9:195-206. doi:10.1016/j.ebiom.2016.06.015.
76. Choi SJ, Lee HC, Kim JH, Park SY, Kim TH, Lee WK, et al. HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I. EMBO J (2016) 35:429-42. doi:10.15252/embj.201592586.
77. van der Veen AG, Ploegh HL. Ubiquitin-like proteins. Annu Rev Biochem (2012) 81:323-57. doi:10.1146/annurev-biochem-093010-153308.
78. Mi Z, Fu J, Xiong Y, Tang H. SUMOylation of RIG-I positively regulates the type I interferon signaling. Protein Cell (2010) 1:275-83. doi:10.1007/s13238-010-0030-1.
79. Nguyen NT, Now H, Kim WJ, Kim N, Yoo JY. Ubiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platform. Sci Rep (2016) 6:23377. doi:10.1038/srep23377.
80. Kim MJ, Hwang SY, Imaizumi T, Yoo JY. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J Virol (2008) 82:1474-83. doi:10.1128/JVI.01650-07.
81. Li MT, Di W, Xu H, Yang YK, Chen HW, Zhang FX, et al. Negative regulation of RIG-I-mediated innate antiviral signaling by SEC14L1. J Virol (2013) 87:10037-46. doi:10.1128/JVI.01073-13.
82. Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, Xin KQ, et al. The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A (2007) 104:14050-5. doi:10.1073/pnas.0704014104.
83. He S, Zhao J, Song S, He X, Minassian A, Zhou Y, et al. Viral pseudo-enzymes activate RIG-I via deamidation to evade cytokine production. Mol Cell (2015) 58:134-46. doi:10.1016/j.molcel.2015.01.036.
84. Zhao J, Li J, Xu S, Feng P. Emerging roles of protein deamidation in innate immune signaling. J Virol (2016) 90:4262-8. doi:10.1128/JVI.01980-15.
85. Habjan M, Andersson I, Klingstrom J, Schumann M, Martin A, Zimmermann P, et al. Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One (2008) 3:e2032. doi:10.1371/journal.pone.0002032.
86. Garcin D, Lezzi M, Dobbs M, Elliott RM, Schmaljohn C, Kang CY, et al. The 5' ends of Hantaan virus (Bunyaviridae) RNAs suggest a prime-and-realign mechanism for the initiation of RNA synthesis. J Virol (1995) 69:5754-62.
87. Wang H, Vaheri A, Weber F, Plyusnin A. Old World hantaviruses do not produce detectable amounts of dsRNA in infected cells and the 5' termini of their genomic RNAs are monophosphorylated. J Gen Virol (2011) 92:1199-204. doi:10.1099/vir.0.029405-0.
88. Schneider U, Schwemmle M, Staeheli P. Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc Natl Acad Sci U S A (2005) 102:3441-6. doi:10.1073/pnas.0405965102.
89. Marq JB, Kolakofsky D, Garcin D. Unpaired 5' ppp-nucleotides, as found in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I. J Biol Chem (2010) 285:18208-16. doi:10.1074/jbc. M109.089425.
90. Lee YF, Nomoto A, Detjen BM, Wimmer E. A protein covalently linked to poliovirus genome RNA. Proc Natl Acad Sci U S A (1977) 74:59-63. doi:10.1073/pnas.74.1.59.
91. Decroly E, Ferron F, Lescar J, Canard B. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol (2012) 10:51-65. doi:10.1038/nrmicro2675.
92. Devarkar SC, Wang C, Miller MT, Ramanathan A, Jiang F, Khan AG, et al. Structural basis for m7G recognition and 2'-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. Proc Natl Acad Sci U S A (2016) 113:596-601. doi:10.1073/pnas.1515152113.
93. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 17:165-72. doi:10.1038/nsmb.1765.
94. Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, et al. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog (2012) 8:e1002916. doi:10.1371/journal.ppat.1002916.
95. Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 109:20661-6. doi:10.1073/pnas.1213559109.
96. Donelan NR, Basler CF, Garcia-Sastre A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 77:13257-66. doi:10.1128/JVI.77.24.13257-13266.2003.
97. Weber M, Sediri H, Felgenhauer U, Binzen I, Banfer S, Jacob R, et al. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe (2015) 17:309-19. doi:10.1016/j.chom.2015.01.005.
98. Uchida L, Espada-Murao LA, Takamatsu Y, Okamoto K, Hayasaka D, Yu F, et al. The dengue virus conceals double-stranded RNA in the intracellular membrane to escape from an interferon response. Sci Rep (2014) 4:7395. doi:10.1038/srep07395.
99. Knoops K, Kikkert M, Worm SH, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol (2008) 6:e226. doi:10.1371/journal.pbio.0060226.
100. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5:439-49. doi:10.1016/j.chom.2009.04.006.
101. Rajsbaum R, Albrecht RA, Wang MK, Maharaj NP, Versteeg GA, Nistal-Villan E, et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog (2012) 8:e1003059. doi:10.1371/journal.ppat.1003059.
102. Kathum OA, Schrader T, Anhlan D, NordhoffC, Liedmann S, Pande A, et al. Phosphorylation of influenza A virus NS1 protein at threonine 49 suppresses its interferon antagonistic activity. Cell Microbiol (2016) 18:784-91. doi:10.1111/cmi.12559.
103. Zheng W, Cao S, Chen C, Li J, Zhang S, Jiang J, et al. Threonine 80 phosphorylation of non-structural protein 1 regulates the replication of influenza A virus by reducing the binding affinity with RIG-I. Cell Microbiol (2016). doi:10.1111/cmi.12643.
104. Jiang J, Li J, Fan W, Zheng W, Yu M, Chen C, et al. Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection. J Virol (2016) 90:6263-75. doi:10.1128/JVI.00549-16.
105. Inn KS, Lee SH, Rathbun JY, Wong LY, Toth Z, Machida K, et al. Inhibition of RIG-I-mediated signaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J Virol (2011) 85:10899-904. doi:10.1128/JVI.00690-11.
106. Chiang JJ, Davis ME, Gack MU. Regulation of RIG-I-like receptor signaling by host and viral proteins. Cytokine Growth Factor Rev (2014) 25:491-505. doi:10.1016/j.cytogfr.2014.06.005.
107. van Kasteren PB, Beugeling C, Ninaber DK, Frias-Staheli N, van Boheemen S, Garcia-Sastre A, et al. Arterivirus and nairovirus ovarian tumor domain-containing deubiquitinases target activated RIG-I to control innate immune signaling. J Virol (2012) 86:773-85. doi:10.1128/JVI.06277-11.
108. Mesman AW, Zijlstra-Willems EM, Kaptein TM, de Swart RL, Davis ME, Ludlow M, et al. Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatases. Cell Host Microbe (2014) 16:31-42. doi:10.1016/j.chom.2014.06.008.
109. Barral PM, Sarkar D, Fisher PB, Racaniello VR. RIG-I is cleaved during picornavirus infection. Virology (2009) 391:171-6. doi:10.1016/j.virol.2009.06.045.
110. Feng Q, Langereis MA, Lork M, Nguyen M, Hato SV, Lanke K, et al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol (2014) 88:3369-78. doi:10.1128/JVI.02712-13.
111. Papon L, Oteiza A, Imaizumi T, Kato H, Brocchi E, Lawson TG, et al. The viral RNA recognition sensor RIG-I is degraded during encephalomyocarditis virus (EMCV) infection. Virology (2009) 393:311-8. doi:10.1016/j.virol.2009.08.009.
112. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, Verbovetskaya V, et al. Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res (2013) 23:1025-42. doi:10.1038/cr.2013.98.
113. Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci U S A (2007) 104:7253-8. doi:10.1073/pnas.0611506104.
114. Mukherjee A, Morosky SA, Delorme-Axford E, Dybdahl-Sissoko N, Oberste MS, Wang T, et al. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog (2011) 7:e1001311. doi:10.1371/journal.ppat.1001311.
115. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein offthe mitochondria to evade innate immunity. Proc Natl Acad Sci U S A (2005) 102:17717-22. doi:10.1073/pnas.0508531102.
116. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol (2010) 185:1158-68. doi:10.4049/jimmunol.0903874.
117. Varga ZT, Grant A, Manicassamy B, Palese P. Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential. J Virol (2012) 86:8359-66. doi:10.1128/JVI.01122-12.
118. Varga ZT, Ramos I, Hai R, Schmolke M, Garcia-Sastre A, Fernandez-Sesma A, et al. The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog (2011) 7:e1002067. doi:10.1371/journal.ppat.1002067.
119. Yoshizumi T, Ichinohe T, Sasaki O, Otera H, Kawabata S, Mihara K, et al. Influenza A virus protein PB1-F2 translocates into mitochondria via Tom40 channels and impairs innate immunity. Nat Commun (2014) 5:4713. doi:10.1038/ncomms5713.
120. Lifland AW, Jung J, Alonas E, Zurla C, Crowe JE Jr, Santangelo PJ. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. J Virol (2012) 86:8245-58. doi:10.1128/JVI.00215-12.
121. Santiago FW, Covaleda LM, Sanchez-Aparicio MT, Silvas JA, Diaz-Vizarreta AC, Patel JR, et al. Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses. J Virol (2014) 88:4572-85. doi:10.1128/JVI.03021-13.
122. Wang D, Fang L, Li P, Sun L, Fan J, Zhang Q, et al. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J Virol (2011) 85:3758-66. doi:10.1128/JVI.02589-10.
123. Zheng D, Chen G, Guo B, Cheng G, Tang H. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res (2008) 18:1105-13. doi:10.1038/cr.2008.294.
124. Dalrymple NA, Cimica V, Mackow ER. Dengue virus NS proteins inhibit RIG-I/MAVS signaling by blocking TBK1/IRF3 phosphorylation: dengue virus serotype 1 NS4A is a unique interferon-regulating virulence determinant. MBio (2015) 6:e553-515. doi:10.1128/mBio.00553-15.
125. Randall CM, Biswas S, Selen CV, Shisler JL. Inhibition of interferon gene activation by death-effector domain-containing proteins from the molluscum contagiosum virus. Proc Natl Acad Sci U S A (2014) 111:E265-72. doi:10.1073/pnas.1314569111.
126. Schroder M, Baran M, Bowie AG. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J (2008) 27:2147-57. doi:10.1038/emboj.2008.143.
127. AlffPJ, Sen N, Gorbunova E, Gavrilovskaya IN, Mackow ER. The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. J Virol (2008) 82:9115-22. doi:10.1128/JVI.00290-08.
128. Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell (2014) 5:369-81. doi:10.1007/s13238-014-0026-3.
129. Wu X, Qi X, Qu B, Zhang Z, Liang M, Li C, et al. Evasion of antiviral immunity through sequestering of TBK1/IKKepsilon/IRF3 into viral inclusion bodies. J Virol (2014) 88:3067-76. doi:10.1128/JVI.03510-13.
130. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol (2000) 74:7989-96. doi:10.1128/JVI.74.17.7989-7996.2000.
131. Irie T, Kiyotani K, Igarashi T, Yoshida A, Sakaguchi T. Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein. J Virol (2012) 86:7136-45. doi:10.1128/JVI.06705-11.
132. Matthews K, Schafer A, Pham A, Frieman M. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. Virol J (2014) 11:209. doi:10.1186/s12985-014-0209-9.
133. Rieder M, Brzozka K, Pfaller CK, Cox JH, Stitz L, Conzelmann KK. Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity. J Virol (2011) 85:842-52. doi:10.1128/JVI.01427-10.
134. Wang S, Wang K, Lin R, Zheng C. Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production. J Virol (2013) 87:12814-27. doi:10.1128/JVI.02355-13.
135. Bentz GL, Shackelford J, Pagano JS. Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation. J Virol (2012) 86:12251-61. doi:10.1128/JVI.01407-12.
136. Arnold MM, Barro M, Patton JT. Rotavirus NSP1 mediates degradation of interferon regulatory factors through targeting of the dimerization domain. J Virol (2013) 87:9813-21. doi:10.1128/JVI.01146-13.
137. Jennings S, Martinez-Sobrido L, Garcia-Sastre A, Weber F, Kochs G. Thogoto virus ML protein suppresses IRF3 function. Virology (2005) 331:63-72. doi:10.1016/j.virol.2004.10.015.
138. Lefort S, Soucy-Faulkner A, Grandvaux N, Flamand L. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J Virol (2007) 81:10950-60. doi:10.1128/JVI.00183-07.
139. Melroe GT, Silva L, Schaffer PA, Knipe DM. Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology (2007) 360:305-21. doi:10.1016/j.virol.2006.10.028.
140. Bravo Cruz AG, Shisler JL. The vaccinia virus K1 ankyrin repeat protein inhibits NF-kB activation by preventing RelA acetylation. J Gen Virol (2016) 97:2691-702. doi:10.1099/jgv.0.000576.
141. Ember SW, Ren H, Ferguson BJ, Smith GL. Vaccinia virus protein C4 inhibits NF-kappaB activation and promotes virus virulence. J Gen Virol (2012) 93:2098-108. doi:10.1099/vir.0.045070-0.
142. Xing J, Ni L, Wang S, Wang K, Lin R, Zheng C. Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP. J Virol (2013) 87:9788-801. doi:10.1128/JVI.01440-13.
143. Wang K, Ni L, Wang S, Zheng C. Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-kappaB activation. J Virol (2014) 88:7941-51. doi:10.1128/JVI.03394-13.
144. Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 79:12828-39. doi:10.1128/JVI.79.20.12828-12839.2005.
145. Lin RJ, Chang BL, Yu HP, Liao CL, Lin YL. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J Virol (2006) 80:5908-18. doi:10.1128/JVI.02714-05.
146. Verweij MC, Wellish M, Whitmer T, Malouli D, Lapel M, Jonjic S, et al. Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms. PLoS Pathog (2015) 11:e1004901. doi:10.1371/journal.ppat.1004901.
147. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 84:3503-15. doi:10.1128/JVI.01161-09.
148. Morrison J, Laurent-Rolle M, Maestre AM, Rajsbaum R, Pisanelli G, Simon V, et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog (2013) 9:e1003265. doi:10.1371/journal.ppat.1003265.
149. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe (2016) 19:882-90. doi:10.1016/j.chom.2016.05.009.
150. Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston JA, et al. Hepatitis C virus targets the interferon-alpha JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett (2013) 587:1571-8. doi:10.1016/j.febslet.2013.03.041.
151. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol (2007) 81:3428-36. doi:10.1128/JVI.02303-06.
152. Ramachandran A, Horvath CM. Paramyxovirus disruption of interferon signal transduction: STATus report. J Interferon Cytokine Res (2009) 29:531-7. doi:10.1089/jir.2009.0070.